InflaRx (IFRX) Receivables (2024 - 2025)
InflaRx's (IFRX) quarterly Receivables came in at $3.7 million in Q2 2025, up 14519.47% year-over-year from N/an in Q2 2024, and up 94.2% quarter-over-quarter from $1.9 million in Q4 2024.
Powered by 
Analysis
InflaRx (IFRX) Receivables (2024 - 2025) Analysis & Trends
InflaRx has disclosed Receivables across 2 years of filings, most recently posting $3.7 million for Q2 2025.
- In Q2 2025, Receivables rose 14519.47% year-over-year to $3.7 million; the TTM figure through Jun 2025 stood at $3.7 million (up 14519.47% YoY), while the FY2024 annual figure was $1.9 million, changed N/A from the prior year.
- Receivables came in at $3.7 million for Q2 2025 at InflaRx, up from $1.9 million in the prior quarter.
- In the past five years, Receivables ranged from a high of $3.7 million in Q2 2025 to a low of $25551.3 in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 10.23 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 5.90 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 2.13 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 6.57 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.93 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 160.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 912.74 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 1.89 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 3.74 Mn |
| Dec 31, 2024 | 1.92 Mn |
| Sep 30, 2024 | 96,172.18 |
| Jun 30, 2024 | 25,551.31 |
| Mar 31, 2024 | 38,285.56 |